GO:0001228 DNA-binding transcription activator activity, RNA polymerase II-specific: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001228 describes a molecular function in which a DNA-binding transcription factor increases transcription of specific gene sets by RNA polymerase II.
• This activity is distinct from general transcription factors and coactivators, which support basal transcription but do not themselves provide sequence-specific activation.
• Activators often work through core promoter proximal regions or distal enhancers and can be regulated by metal ions such as zinc or copper.
• The function is essential for developmental gene programs, stress responses, and cell identity, and its dysregulation is linked to cancer and other diseases.
• Key experimental approaches include reporter assays, chromatin immunoprecipitation, RNA-seq, and CRISPR-based knockout or knock-in models.
• EDITGENE provides CRISPR services to interrogate GO:0001228-related genes, including knockout, point mutation, knock-in, overexpression, and library screening.
Description
GO:0001228, DNA-binding transcription activator activity, RNA polymerase II-specific, is a molecular function term that defines the ability of a transcription factor to bind DNA in a sequence-specific manner and activate or increase transcription of target genes transcribed by RNA polymerase II. This activity is central to gene regulation because it converts developmental, environmental, or metabolic signals into changes in gene expression programs. Unlike general transcription factors that are required for basal transcription of most genes, activators annotated with GO:0001228 provide specificity and regulatory input to particular gene sets. The term is widely used in functional genomics, cancer biology, and developmental biology to describe proteins such as sequence-specific activators that interact with core promoter or enhancer regions. Understanding this activity helps researchers interpret how mutations or expression changes in transcription factors can rewire cellular states. Experimental evidence from studies on RNA polymerase II transcription and its coactivators supports the view that activation involves coordinated recruitment of coactivators and general transcription machinery. The QuickGO definition emphasizes positive regulation, distinguishing this term from DNA-binding repressors or general transcription factors. As a result, GO:0001228 is a key annotation for any gene product that directly binds DNA and stimulates RNA polymerase II transcription.
DNA-binding transcription activator activity, RNA polymerase II-specific At A Glance
| GO ID | GO:0001228 |
|---|---|
| GO term | DNA-binding transcription activator activity, RNA polymerase II-specific |
| Ontology | molecular_function |
| Synonym | RNA polymerase II transcriptional activator activity; transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding; zinc ion regulated core promoter proximal region sequence-specific DNA binding RNA polymerase II transcription factor activity involved in positive regulation of transcription |
| Major function | Sequence-specific DNA binding and positive regulation of RNA polymerase II transcription |
| Definition source | QuickGO |
| Related activity | DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981) |
| Regulation | Can be modulated by metal ions such as zinc or copper and by interaction with coactivators |
| Example evidence | Reporter assays, chromatin immunoprecipitation, and RNA-seq in knockout or overexpression models |
What Is GO:0001228?
In simple terms, GO:0001228 describes a protein that binds to a specific DNA sequence and turns on or increases the transcription of nearby genes that are transcribed by RNA polymerase II. This is a molecular function: it is the activity of a single gene product, not a whole pathway or cellular structure. The activator typically recognizes regulatory regions such as promoters or enhancers and recruits coactivators or general transcription factors to stimulate RNA polymerase II. The definition excludes general transcription factors that act at all promoters and repressors that decrease transcription. It also includes variants regulated by metal ions such as zinc or copper, as reflected in the synonyms.
Why Is DNA-binding transcription activator activity, RNA polymerase II-specific Important in Cell Biology?
GO:0001228 is important because it defines the molecular activity that drives cell-type-specific and signal-responsive gene expression. Dysregulation of sequence-specific transcriptional activators can lead to inappropriate activation of oncogenes, loss of tumor suppressors, or failure of developmental programs. Because activators are often rate-limiting for gene expression, they are attractive targets for experimental perturbation and therapeutic intervention. Understanding this activity also helps interpret non-coding regulatory variants and somatic mutations in cancer genomes. In addition, many activators are regulated by cofactors and post-translational modifications, making them nodes for signaling integration.
• Controls developmental gene expression programs and cell fate decisions.
• Mediates signal-dependent transcription in response to hormones, growth factors, and stress.
• Frequently mutated or dysregulated in cancer, including transcription factors such as HIC1.
• Provides specificity beyond general transcription factors, enabling selective gene activation.
• Can be regulated by metal ions, linking nutrient status to transcription.
• Serves as a target for CRISPR knockout, knock-in, and overexpression studies to test causality.
• Involved in immune and inflammatory gene programs through activators such as NF-κB components.
• Enables interpretation of enhancer and promoter variants in non-coding regions.
• Supports synthetic biology approaches to engineer gene expression.
• Guides drug discovery for transcription factor-driven diseases.
What Happens During DNA-binding transcription activator activity, RNA polymerase II-specific?
Sequence-specific DNA binding
In simple terms: The activator protein first finds and binds to a specific DNA sequence in a promoter or enhancer.
Activators annotated with GO:0001228 recognize short DNA motifs in regulatory regions. This binding is sequence-specific and is the first step that distinguishes one activator from another. The QuickGO synonyms include core promoter proximal region and distal enhancer binding, indicating that activators can act at different regulatory elements. DNA binding is often mediated by structured domains such as zinc fingers, helix-turn-helix, or basic leucine zipper motifs. Mutations in these domains can abolish DNA binding and transcriptional activation, as seen in computational analyses of HIC1 SNPs.
Recruitment of coactivators and general transcription machinery
In simple terms: After binding DNA, the activator recruits other proteins that help RNA polymerase II start transcription.
Once bound to DNA, activators interact with coactivators such as PC4/Sub1, which have multiple functions in RNA polymerase II transcription. They also facilitate assembly of general transcription factors including TFIIA, TFIIB, and TBP at the promoter. The yeast TFIIA studies showed that distinct functional regions of TFIIA are required for basal and activated transcription, highlighting the interplay between activators and the general machinery. In metazoans, TFIIA variants such as TFIIAtau can stimulate TBP-DNA binding and transcription activation in a testis-specific manner.
Stimulation of RNA polymerase II elongation and re-initiation
In simple terms: The activator not only starts transcription but can also help RNA polymerase II continue and re-initiate for high expression.
Activation is not limited to initiation. Coactivators such as PC4/Sub1 have been implicated in multiple steps of RNA polymerase II transcription, including elongation and re-initiation. This multilayered regulation ensures that activated genes can achieve high expression levels. The retinoid-dependent transcription studies showed that RAR/RXR activators connect to TBP and E1A/E1A-LA, illustrating how activators integrate with elongation and coactivator complexes. Thus, GO:0001228 encompasses positive regulation at several steps of the transcription cycle.
Metal ion regulation of activator function
In simple terms: Some activators need metal ions like zinc or copper to fold correctly or bind DNA.
The synonyms of GO:0001228 explicitly include metal ion regulated variants, such as zinc ion regulated core promoter proximal region sequence-specific DNA binding. Zinc finger activators require zinc for structural integrity, and copper-regulated activators can respond to copper availability. This links nutrient and metal homeostasis to transcriptional output. Experimental evidence from the Siling decoction study showed modulation of AKT/IKKβ/NFκB signaling, a pathway that includes activators with metal-sensitive components. Researchers should consider metal supplementation or chelation when studying such activators.
Key Genes Involved in GO:0001228 DNA-binding transcription activator activity, RNA polymerase II-specific
The following genes and proteins are representative of GO:0001228 activity, based on published literature and their roles in RNA polymerase II transcription activation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HIC1 | Sequence-specific transcriptional repressor/activator with zinc finger domain | SNP analysis and cancer studies; mutations affect DNA binding |
| PC4/Sub1 | Coactivator with multiple functions in RNA polymerase II transcription | Model for coactivator-dependent activation |
| TFIIA | General transcription factor that stabilizes TBP-DNA binding | Distinct regions required for basal and activated transcription |
| TFIIAtau | Testis-specific TFIIA variant | Stimulates TBP-DNA binding and transcription activation |
| TBP | TATA-binding protein | Core promoter recognition and integration of activator signals |
| RAR/RXR | Retinoid receptors that activate transcription | Retinoid-dependent transcription and TBP connection |
| NF-κB components | Signal-dependent activators of inflammatory genes | Modulated by AKT/IKKβ/NFκB pathway |
| AraC/XylS family activators | Bacterial transcriptional activators | Class II activation determinants in RNA polymerase alpha subunit |
| TFIIB-related factor | RNA polymerase III transcription factor | Comparison of polymerase-specific activation mechanisms |
| E1A/E1A-LA | Viral coactivators that interact with TBP | Retinoid-dependent transcription connection |
| SP1 | Zinc finger activator of housekeeping and inducible genes | Metal ion regulated DNA binding |
| CTCF | Insulator and activator with zinc finger domain | Chromatin architecture and enhancer function |
| MYC | Oncogenic activator of growth genes | Cancer and CRISPR knockout models |
| TP53 | Tumor suppressor with activation and repression functions | Mutational analysis and cancer models |
| NFAT | Calcium-regulated activator of immune genes | Signal-dependent transcription |
| STAT3 | Cytokine-activated transcription factor | Cancer and inflammation models |
| HIF1A | Hypoxia-inducible activator | Metabolic and oxygen-sensing pathways |
How Is DNA-binding transcription activator activity, RNA polymerase II-specific Regulated?
GO:0001228 activity is regulated at multiple levels. Metal ions such as zinc and copper can directly influence DNA binding by metal-responsive activators. Signaling pathways, including AKT/IKKβ/NFκB, modulate activator phosphorylation and nuclear localization. Coactivators such as PC4/Sub1 can be limiting and are themselves regulated. General transcription factors like TFIIA have distinct functional regions that determine the efficiency of activated transcription. Retinoid signaling provides a classic example of ligand-dependent activation through RAR/RXR and TBP interactions. Post-translational modifications, including phosphorylation and acetylation, often control activator stability and interactions. Therefore, researchers should consider both cell-intrinsic and environmental factors when studying this activity.
DNA-binding transcription activator activity, RNA polymerase II-specific and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HIC1 | Cancer (hypermethylation, mutations) | CRISPR knockout and point mutation in cancer cell lines |
| NF-κB components | Inflammatory and fibrotic diseases | Knockout mice and reporter assays |
| MYC | Multiple cancers | Overexpression and knockout models |
| STAT3 | Cancer and inflammation | Point mutation knock-in and knockout |
| TFIIA/TFIIAtau | Developmental and testis-specific transcription | Knockout and tagged knock-in in cell lines |
Cancer
Dysregulation of sequence-specific transcriptional activators is a hallmark of many cancers. HIC1, a zinc finger transcription factor, is frequently hypermethylated or mutated in cancer, and computational analysis of its SNPs suggests that coding variants can alter DNA binding and transcriptional activity. Oncogenic activators such as MYC and STAT3 drive proliferation and survival gene programs. Targeting these activators or their coactivators is an active therapeutic strategy. CRISPR knockout and point mutation models are essential to determine which mutations are driver versus passenger events.
Inflammatory and metabolic diseases
NF-κB and other signal-dependent activators are central to inflammatory gene expression. The Siling decoction study showed that modulation of AKT/IKKβ/NFκB signaling ameliorates renal fibrosis, highlighting the role of activators in disease. Metabolic stress can also regulate activators through nutrient-sensing pathways. Metal ion imbalance may affect zinc finger activators, linking diet and environment to transcriptional output. Experimental models include knockout mice and cell lines with reporter assays.
Developmental disorders
Many developmental transcription factors are annotated with GO:0001228. Mutations in these activators can cause haploinsufficiency or dominant-negative effects. The general transcription factor TFIIA and its testis-specific variant TFIIAtau illustrate tissue-specific activation requirements. Studying these factors in model organisms and stem cell-derived models can reveal mechanisms of developmental gene regulation.
From DNA-binding transcription activator activity, RNA polymerase II-specific-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of activator function reduce target gene expression? | CRISPR knockout (KO) cell line |
| Does a specific point mutation alter DNA binding or activation? | Point mutation knock-in |
| Does tagging the activator affect localization or interactions? | Tagged knock-in (e.g., GFP, HA) |
| Does overexpression activate target genes? | Overexpression stable cell line |
| Which coactivators are required for activation? | Knockout of coactivator genes |
| Can a disease-associated SNP affect activator function? | Point mutation knock-in and reporter assay |
How to Study the DNA-binding transcription activator activity, RNA polymerase II-specific Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Luciferase reporter assay | Transcriptional activation of a target promoter | Validate GO:0001228 activity and mutations |
| ChIP-qPCR/ChIP-seq | Genomic binding sites of the activator | Confirm sequence-specific DNA binding |
| RNA-seq | Changes in gene expression | Identify activated gene sets |
| Co-immunoprecipitation | Protein-protein interactions | Discover coactivators and general transcription factors |
| Mass spectrometry | Proteomic composition of complexes | Map activation complex components |
| CRISPR knockout | Loss-of-function phenotype | Test causality of activator in gene regulation |
| CRISPR knock-in | Effects of specific mutations or tags | Model disease variants and study localization |
| Overexpression | Gain-of-function effects | Test sufficiency of activator for gene activation |
Reporter assays
Luciferase or fluorescent reporters driven by a promoter containing the activator binding site are used to measure transcriptional activation. This method is standard for validating GO:0001228 activity and testing mutations. Controls include mutant binding sites and empty vectors.
Chromatin immunoprecipitation (ChIP)
ChIP followed by qPCR or sequencing identifies genomic binding sites of the activator. It confirms sequence-specific DNA binding in vivo and can be combined with RNA-seq to link binding to gene activation.
RNA-seq and transcriptomics
RNA-seq measures changes in target gene expression after knockout, knockdown, or overexpression of the activator. This provides genome-wide evidence of positive regulation and helps identify direct versus indirect targets.
Proteomics and co-immunoprecipitation
Mass spectrometry and co-IP identify coactivators and general transcription factors that interact with the activator. These methods reveal the composition of activation complexes.
How CRISPR Can Be Used to Study GO:0001228 DNA-binding transcription activator activity, RNA polymerase II-specific
Knockout
CRISPR knockout of a gene encoding a GO:0001228 activator can abolish its function and reveal target genes. This is the most direct way to test whether an activator is required for a specific gene expression program. Knockout cell lines are also used to validate antibody specificity and to create isogenic controls.
Point Mutation
Point mutation knock-in allows researchers to introduce disease-associated or functional variants into the endogenous locus. This preserves physiological expression levels and regulatory context. For example, SNPs in HIC1 can be modeled to test effects on DNA binding and transcription.
Knock-in
Tagged knock-in (e.g., GFP, HA, or degron) enables visualization, purification, or rapid degradation of the activator. This is useful for ChIP, imaging, and proteomics. Knock-in of reporter cassettes can also monitor activator expression in real time.
Overexpression
Overexpression of an activator can test sufficiency for gene activation and phenotypic changes. It is often used in cancer models to study oncogenic activation. Combining overexpression with RNA-seq identifies the full set of activated genes.
How EDITGENE Supports DNA-binding transcription activator activity, RNA polymerase II-specific Research
Researchers studying DNA-binding transcription activator activity, RNA polymerase II-specific-related genes often need to determine whether a candidate gene is causally involved in a specific transcriptional program or disease phenotype. This requires precise genetic models that can isolate the function of the activator from coactivators and general transcription factors. EDITGENE provides end-to-end CRISPR services to generate such models, from knockout to knock-in and overexpression, along with screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for DNA-binding transcription activator activity, RNA polymerase II-specific research.
Frequently Asked Questions About DNA-binding transcription activator activity, RNA polymerase II-specific
What is GO:0001228?
GO:0001228 is a Gene Ontology molecular function term for DNA-binding transcription activator activity, RNA polymerase II-specific. It describes proteins that bind specific DNA sequences and increase transcription of target genes by RNA polymerase II.
What genes are involved in DNA-binding transcription activator activity, RNA polymerase II-specific?
Genes include HIC1, MYC, STAT3, NF-κB components, and many zinc finger transcription factors. These encode sequence-specific activators that regulate RNA polymerase II transcription.
How is GO:0001228 different from general transcription factor activity?
General transcription factors are required for basal transcription of most genes, while GO:0001228 activators provide sequence-specific positive regulation of particular gene sets.
What diseases are linked to defects in transcription activators?
Cancer, inflammatory diseases, and developmental disorders can result from mutations or dysregulation of sequence-specific activators such as HIC1 and NF-κB.
How can I study GO:0001228 activity in the lab?
Common methods include luciferase reporter assays, ChIP-seq, RNA-seq, and CRISPR knockout or knock-in models.
What are the synonyms of GO:0001228?
Synonyms include RNA polymerase II transcriptional activator activity, transcriptional activator activity RNA polymerase II core promoter proximal region sequence-specific binding, and zinc ion regulated core promoter proximal region sequence-specific DNA binding RNA polymerase II transcription factor activity involved in positive regulation of transcription.
Can CRISPR be used to study transcription activators?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are widely used to test the function of transcription activators.
What is the role of metal ions in GO:0001228?
Some activators require zinc or copper for DNA binding or structural stability, as reflected in the metal ion regulated synonyms.
Which coactivators interact with GO:0001228 activators?
Coactivators such as PC4/Sub1 and general transcription factors like TFIIA and TBP interact with activators to stimulate transcription.
How does EDITGENE support research on transcription activators?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services for transcription activator genes.
Conclusion
GO:0001228, DNA-binding transcription activator activity, RNA polymerase II-specific, is a fundamental molecular function that drives selective gene expression. It encompasses sequence-specific DNA binding and positive regulation of RNA polymerase II transcription, often through coactivator recruitment and metal ion-dependent mechanisms. Dysregulation of these activators contributes to cancer, inflammation, and developmental disorders, making them important research targets. Advances in CRISPR-based models and functional genomics now allow precise interrogation of activator function in physiological contexts. Researchers can leverage these tools to uncover new mechanisms and therapeutic opportunities.
References
- 1. Zeng L et al.. 2024. Siling decoction ameliorates adenine-induced renal fibrosis in rats by the AKT/IKKβ/NFκB signaling pathway.. Phytomedicine 135:156228 PMID: 39550923
- 2. Calvo O et al.. 2005. The transcriptional coactivator PC4/Sub1 has multiple functions in RNA polymerase II transcription.. EMBO J 24(5):1009-20 PMID: 15692559
- 3. Annanya A et al.. 2024. Computational Analysis of Single Nucleotide Polymorphisms in Human HIC1 Gene.. Cureus 16(3):e56664 PMID: 38646326
- 4. Ozer J et al.. 2000. A testis-specific transcription factor IIA (TFIIAtau) stimulates TATA-binding protein-DNA binding and transcription activation.. J Biol Chem 275(1):122-8 PMID: 10617594
- 5. Meyer M et al.. 1996. Retinoid-dependent transcription: the RAR/RXR-TBP-EIA/EIA-LA connection.. Biochem Soc Symp 62:97-109 PMID: 8971343
- 6. Egan SM et al.. 2000. Transcription activation by a variety of AraC/XylS family activators does not depend on the class II-specific activation determinant in the N-terminal domain of the RNA polymerase alpha subunit.. J Bacteriol 182(24):7075-7 PMID: 11092872
- 7. Kang JJ et al.. 1995. Analysis of the yeast transcription factor TFIIA: distinct functional regions and a polymerase II-specific role in basal and activated transcription.. Mol Cell Biol 15(3):1234-43 PMID: 7862117
- 8. Colbert T et al.. 1992. A yeast TFIIB-related factor involved in RNA polymerase III transcription.. Genes Dev 6(10):1940-9 PMID: 1398071
